Oncogenic RIT1 mutations in lung adenocarcinoma by Berger, A H et al.
 
Oncogenic RIT1 mutations in lung adenocarcinoma
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Berger, A H, M Imielinski, F Duke, J Wala, N Kaplan, G-X Shi,
D A Andres, and M Meyerson. 2014. “Oncogenic RIT1
mutations in lung adenocarcinoma.” Oncogene 33 (35): 4418-
4423. doi:10.1038/onc.2013.581.
http://dx.doi.org/10.1038/onc.2013.581.
Published Version doi:10.1038/onc.2013.581
Accessed February 16, 2015 11:33:47 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:12987403
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-
of-use#LAAOPEN
ORIGINAL ARTICLE
Oncogenic RIT1 mutations in lung adenocarcinoma
AH Berger
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Lung adenocarcinoma is comprised of distinct mutational subtypes characterized by mutually exclusive oncogenic mutations in
RTK/RAS pathway members KRAS, EGFR, BRAF and ERBB2, and translocations involving ALK, RET and ROS1. Identiﬁcation of these
oncogenic events has transformed the treatment of lung adenocarcinoma via application of therapies targeted toward speciﬁc
genetic lesions in stratiﬁed patient populations. However, such mutations have been reported in only B55% of lung
adenocarcinoma cases in the United States, suggesting other mechanisms of malignancy are involved in the remaining cases. Here
we report somatic mutations in the small GTPase gene RIT1 in B2% of lung adenocarcinoma cases that cluster in a hotspot near
the switch II domain of the protein. RIT1 switch II domain mutations are mutually exclusive with all other known lung
adenocarcinoma driver mutations. Ectopic expression of mutated RIT1 induces cellular transformation in vitro and in vivo, which can
be reversed by combined PI3K and MEK inhibition. These data identify RIT1 as a driver oncogene in a speciﬁc subset of lung
adenocarcinomas and suggest PI3K and MEK inhibition as a potential therapeutic strategy in RIT1-mutated tumors.
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INTRODUCTION
Lung adenocarcinomas contain characteristic, mutually exclusive
mutations in receptor tyrosine kinase (RTK) and RAS pathway
oncogenes including frequent mutation of KRAS or EGFR in B30 or
10% of US cases, respectively.
1–13 Rarely, translocations are seen
involving EML4 and ALK (1–4%), RET (1%) or ROS1 (2%)
2,5 (The
Cancer Genome Atlas, manuscript submitted). Additional rare
oncogenic mutations are seen in HRAS, NRAS, BRAF, ERBB2, MET
and MAP2K1.
1,2 Together these oncogenic events are found in
B55% of lung adenocarcinomas in the US population.
2 The
importance of identifying such ‘driver’ mutations is exempliﬁed by
the success of targeted therapies directed against these events—
the prototypical example being the use of the small molecule EGFR
inhibitors Iressa (geﬁtinib) and Tarceva (erlotinib) in EGFR-mutated
lung adenocarcinoma.
14 Among patients with EGFR mutations,
single-line EGFR-targeted therapy signiﬁcantly extends progression-
free survival compared with conventional chemotherapy.
7,8 Patients
without EGFR mutations, however, typically do not beneﬁt from
targeted therapy, underscoring the need to genotype patient
tumor resections and/or biopsies to guide appropriate treatment
decisions. Modeling this paradigm, clinical trials of the ALK inhibitor
crizotinib for treatment of tumors with EML4-ALK translocation were
rapidly reported
15 only 3 years after the identiﬁcation of the EML4-
ALK event.
5 Therefore, continued identiﬁcation of oncogenic driver
genes in the remaining B45% of ‘oncogene-negative’ lung
adenocarcinoma cases may allow further patient stratiﬁcation and
targeted therapies.
Recent genomic analyses of lung adenocarcinoma have
identiﬁed novel mutations in diverse genes, but few additional
oncogenic mutations have been identiﬁed that display
mutual exclusivity with known lung adenocarcinoma driver
oncogenes.
1,16 Here we report the genomic and functional
characterization of somatic RIT1 mutations that we identify as
novel driver mutations in lung adenocarcinoma.
RESULTS
To identify rare oncogenic driver mutations, we and others in The
Cancer Genome Atlas (TCGA) Research Network performed a
targeted analysis of ‘oncogene-negative’ tumors that lack muta-
tions in the known lung adenocarcinoma driver oncogenes KRAS,
EGFR, BRAF, ERBB2, MAP2K1, MET, HRAS, NRAS and/or fusions
involving ALK, RET or ROS1 (TCGA, manuscript submitted). In 87
‘oncogene-negative’ samples lacking mutations/fusions in the
known driver genes, RIT1 (Ras-like in all tissues) was among the top
signiﬁcantly mutated genes. 5/87 samples in this group harbored
somatic RIT1 mutations. In contrast, no mutations in RIT1 were
found in the 143 samples containing known driver oncogenic
mutations (Po0.01 by Fisher’s exact test). Moreover, we identiﬁed
ﬁve additional RIT1-mutant samples in sequence data from an
independent cohort of 183 lung adenocarcinomas.
1
In total, non-synonymous somatic mutations of RIT1 were
identiﬁed in 10/413 (2.4%) lung adenocarcinomas subjected to
whole exome sequencing (Figure 1a, Supplementary Table 1).
Mutations in RIT1 consisted of missense mutations and small in-
frame insertion/deletions. In all, 7/10 RIT1 mutations were
clustered near the switch II domain region (Figures 1a and b),
including three recurrent p.M90I mutations. The switch II domain
in RIT1 is homologous to the switch II region in RAS genes that
contains glutamine 61 (Supplementary Figure 1), which is directly
involved in GTP hydrolysis and also a hotspot of mutation in RAS
genes.
17 This switch II domain hotspot is distinct from the P29
hotspot in RAC genes recently reported in melanoma and other
cancers
18–20 (Supplementary Figure 1).
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www.nature.com/oncRecurrent alteration of RIT1 alanine 77 was also observed; one
of the ten mutated samples from this analysis harbored a p.A77P
mutation and an additional TCGA sample (TCGA-73-4666)
harbored a p.A77S mutation. TCGA-73-4666 was excluded from
the 230 tumor TCGA data set due to lack of data from its paired
normal sample. We hence cannot rule out that p.A77S represents
a rare germline variant, though it is unlikely given its absence in
sequence data generated from 1092 normal genomes by the 1000
Genomes Project.
21
All seven samples with switch II domain RIT1 mutations lacked
oncogenic driver mutations in EGFR, KRAS, BRAF, ERBB2, HRAS,
NRAS and MAP2K1. This pattern of mutational mutual exclusivity is
consistent with the possibility that RIT1 switch II domain
mutations may function as RAS/RTK pathway lung adenocarci-
noma oncogenes. However, one of three non-switch II domain
mutations, p.R122L, co-occurred with a KRAS mutation
(Supplementary Figure 2).
We surveyed recent exome sequencing data from other diverse
cancer types to determine whether RIT1 is mutated in malig-
nancies other than lung adenocarcinoma. Most tumor types had
no mutations, or rare RIT1 variants of unknown signiﬁcance
(Supplementary Table 2). However, one sample each from acute
myelogenous leukemia
22 and cervical carcinoma sequencing
studies harbored the RIT1 p.M90I variant seen recurrently in
lung adenocarcinoma. In line with these observations, somatic
RIT1 mutation was recently reported in myeloid malignancies.
23
The mutations observed in myeloid malignancies overlap with the
mutations we report in lung adenocarcinoma (F82L, M90I) and
include additional mutations clustering in the switch II domain.
To test whether mutated RIT1 is capable of inducing cellular
transformation, we expressed wild-type or mutated RIT1 cDNA
constructs in NIH3T3 cells and assayed the ability of these cells to
form colonies in soft agar. A constitutively active form of RIT1, RIT1
Q79L,
24 was used as a positive control. With the exception of RIT1
Q40L, all other RIT1 mutations robustly induced colony formation
of NIH3T3 cells in soft agar (Figure 2a). To conﬁrm that these cells
were indeed transformed, we injected RIT1-transduced cells
subcutaneously into nude mice and assessed tumor-forming
capability. Six of six switch II domain mutations induced signiﬁcant
tumor formation by 3 weeks post-injection, comparable to
transformation induced by KRAS G12V or EGFR L858R (Figure 2b
and Supplementary Figure 3), whereas transformation capability
of non-switch II domain mutations varied. RIT1 Q40L, although
consistently less active than other RIT1 variants, showed
intermediate transforming capability in the xenograft assay
(Supplementary Figure 3). It remains possible that RIT1 Q40L is
weakly activating, and should be noted that RIT1 Q40 is
homologous to KRAS Q22, which is found mutated in Noonan
syndrome
25 and rarely in somatic cancers.
In addition to the lung adenocarcinoma mutations, we tested
the transforming capability of RIT1 mutations reported in myeloid
malignancies
23 or curated in COSMIC
26 from diverse tumor
types (Supplementary Table 3). Consistent with the lung
adenocarcinoma data, transforming mutations were mainly
clustered in the switch II domain. We identiﬁed transforming
RIT1 mutations in salivary gland carcinoma, endometrial carci-
noma, myeloid malignancies and melanoma. These data indicate
that rare RIT1 mutations may have a role in the pathogenesis of
diverse cancers.
RIT1 mutation is mutually exclusive with mutations in other
RAS/RTK-pathway genes, so we hypothesized that RIT1 may
activate PI3K and MEK. To investigate the signaling changes
induced by mutated RIT1, we expressed wild-type or mutated RIT1
in PC6 cells and analyzed downstream signaling changes by
western blot. Transformation potential of RIT1 mutants correlated
with their ability to activate MEK and ERK pathways; all RIT1
mutations with the exception of RIT1 Q40L induced phosphoryla-
tion of MEK and ERK (Figure 2c). Treatment of RIT1-expressing cells
with the speciﬁc MEK inhibitor, PD98059, completely inhibited
RIT1-induced ERK phosphorylation, indicating that RIT1 induces
ERK phosphorylation via activation of MEK (Figure 2d). In addition
to MEK/ERK signaling, we observed robust activation of PI3K/AKT
signaling by mutated RIT1. Oncogenic RIT1 mutants induced
phosphorylation of AKT (S473 and T308), which could be inhibited
by treatment with the PI3K/mTOR inhibitor LY294002 (Figure 2e).
RIT1-activated MEK and PI3K signaling independently, as MEK
inhibition failed to impair AKT phosphorylation and PI3K/mTOR
inhibition failed to impair ERK phosphorylation.
To determine if activation of MEK and PI3K was responsible for
RIT1-induced transformation, we assayed the ability of RIT1
mutants to form colonies in soft agar in the presence or absence
of different kinase inhibitors. Either MEK inhibition with 1mM AZD-
6244 or PI3K/mTOR inhibition with 1mM GDC-0941 signiﬁcantly
impaired colony formation (Figure 2f), whereas treatment with the
EGFR inhibitor erlotinib (1mM) showed no effect. Combination MEK
and PI3K inhibition almost completely abrogated colony forma-
tion (Figure 2f).
Given the prevalence of RIT1 mutation in primary human lung
adenocarcinomas, we hypothesized that human lung adenocarci-
noma cell lines may also harbor mutations in RIT1 and that
identiﬁcation of these cell lines would facilitate study of RIT1
Figure 1. Somatic RIT1 mutations in lung adenocarcinoma. (a)2 D
protein structure schematics of RIT1 and KRAS with major protein
domains shaded as indicated. Numbers indicate amino-acid posi-
tions. Each box represents an independent somatic RIT1 mutation
with missense and in-frame indel mutations represented in black or
blue, respectively. Arrows indicate two mutational hotspots in KRAS.
(b) Predicted protein structure of RIT1. A homology model of RIT1
was generated from an alignment with HRAS (1AGP) using SWISS
model and displayed using PYMOL. Amino acids near the switch II
domain found mutated in this study are highlighted in yellow, in
addition to Q79, which is shown for reference.
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pattern of RIT1 mutation mutual-exclusivity with driver mutations
in primary samples, we focused our efforts on ‘oncogene-negative’
human non-squamous non-small cell lung cancer cell lines. We
curated the mutational status of all known lung adenocarcinoma
driver genes from non-squamous non-small cell lung cancer
lines in the Cancer Cell Line Encyclopedia.
27 Among 35
‘oncogene-negative’ cell lines, NCI-H2110 showed the highest
level of RIT1 mRNA expression (Supplementary Figure 4 and
Supplementary Table 4). Next, we sequenced the switch II domain
of RIT1 in cDNA from 19 ‘oncogene-negative’ cell lines and 3
‘oncogene-positive’ cell lines (Supplementary Table 5). In all, 1/19
‘oncogene-negative’ and 0/3 ‘oncogene-positive cell lines’ had a
non-synonymous change in RIT1; NCI-H2110 cells harbored the
p.M90I mutation also seen in human primary lung adenocarcino-
mas (Figure 3a).
To determine if RIT1-mediated PI3K and MEK activation are
involved in RIT1-mutated human lung adenocarcinoma, we
interrogated the role of these pathways in NCI-H2110 cells.
Using lentiviral delivery of RIT1-targeting (shRIT1-1, shRIT1-2 and
shRIT1-3) and non-targeting (shLacZ) short hairpin RNA, we
knocked down RIT1 levels in NCI-H2110 and NCI-H1299 cells, the
latter of which express low or no RIT1 (Figure 3b). Knockdown of
RIT1 in NCI-H2110 cells resulted in loss of AKT phosphorylation
and a reduction in MEK and ERK phosphorylation, whereas
expression of the same hairpins in NCI-H1299 cells had no
consistent effect. Therefore, RIT1 regulates PI3K and MEK signaling
in NCI-H2110 cells.
Given the potent ability of the PI3K/mTOR inhibitor GDC-0941
to inhibit RIT1-induced cellular transformation (Figure 2f), we
sought to determine whether GDC-0941 would impair the growth
of RIT1-mutated human lung adenocarcinoma cells. NCI-H2110
Figure 2. Mutated RIT1 induces cellular transformation via activation of MEK and PI3K. (a) Soft agar transformation assay in NIH3T3 cells. Cells
were transduced with retrovirus to ectopically express wild-type (WT) or mutated RIT1 constructs or empty vector (control), then plated in soft
agar (Methods). Colonies were visualized at 14 days and quantiﬁed using CellProﬁler. Top panel, data shown are meanþs.e.m. of triplicate
wells. Data shown are representative of at least three independent experiments. *Po0.05 by two-tailed t-test. Bottom panels, western blot
showing expression of RIT1 or vinculin (loading control). ‘INS’, T76_insTLDT. (b) Tumor growth of xenografts of NIH3T3 cells with or without
expression of RIT1. Data shown is meanþs.e.m. of nine replicates per construct. *Po0.01 by two-tailed t-test. Data shown are representative
of at least two independent experiments per construct. (c) Western blot of PC6 cell lysates following transfection of wild-type or mutant RIT1
or vector control (‘Emp’). Data shown is representative of at least three independent experiments. (d) Western blot of PC6 lysates following
transfection of FLAG-RIT1 constructs or vector control (‘Emp’) in the presence or absence of 10mM PD98059. Cells were serum starved for 5h
prior to lysis. (e) Western blot of PC6 cell lysates generated after transfection of FLAG-RIT1 mutant constructs in the presence or absence of
10mM LY294002. Cells were serum starved for 5h prior to lysis. (f) Soft agar colony formation of NIH3T3 cells stably expressing RIT1 M90I or
RIT1 Q79L in the presence or absence of 1mM erlotinib, GDC-0941, AZD-6244 or GDC-0941/AZD-6244 or vehicle control (dimethylsulfoxide).
5 10
3 cells were suspended in a top agar solution together with each respective drug to a ﬁnal concentration of 1mM in triplicate. After 15
days, colonies were photographed and quantiﬁed using CellProﬁler. *Po0.05.
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ﬂanks of nude mice. After tumors were established, mice were
dosed daily with 150mg/kg GDC-0941 as previously described.
28
GDC-0941 signiﬁcantly impaired tumor growth (Figure 3c), result-
ing in markedly smaller tumor masses in the GDC-0941-treated
group at the experimental end point (Figure 3d).
DISCUSSION
RIT1 encodes a RAS-family small GTPase
24,29 with signiﬁcant domain
and sequence homology to KRAS, HRAS and NRAS (Figures 1a and
b). Although RIT1 is ubiquitously expressed, expression of its closest
homolog, RIT2/RIN, is restricted to the nervous system.
29 Like RAS
proteins, RIT1 possesses intrinsic GTP hydrolysis activity,
24 which can
be inactivated by construction of a point mutation, Q79L, at the
glutamine homologous to Q61 in RAS.
24 Expression of Q79L RIT1 is
sufﬁcient to transform NIH3T3 cells
30 and induces activation of p38,
ERK or AKT signaling pathways depending on cellular context.
31,32
Interestingly, the codon for Q79 also provides the 50 splice site for
intron 4–5 of RIT1; mutation of glutamine 79 to leucine would be
predicted to disrupt the splice site, which may make natural Q79L
mutation incompatible with RIT1 expression.
In PC6 cells, a derivative of the PC12 pheochromocytoma line
commonly used for study of RAS/MAPK signaling and neuronal
differentiation,
33,34 RIT1 activates MEK/ERK through direct binding
with BRAF.
31 Moreover, RIT1 activity is induced by stimulation with
EGF or NGF in PC6 cells.
31 Recently, studies in Rit knockout mice
demonstrated that Rit promotes survival after oxidative stress
through activation of a p38-AKT-BAD signaling cascade.
35 Rit
 /  cells are hypersensitive to apoptosis after exposure to
reactive oxygen species (ROS) whereas cells expressing Q79L RIT1
are protected.
35
The RIT1 switch II domain mutations identiﬁed here in B2% of
lung adenocarcinomas deﬁne a new subset of lung adenocarci-
noma. RIT1 switch II domain mutations are mutually exclusive with
all other known lung adenocarcinoma oncogenes and rapidly
induce transformation in vitro and in vivo. RIT1 mutation induces
activation of PI3K and MEK signaling and these pathways are
required for RIT1-mediated cellular transformation. These experi-
mental and observational data indicate that RIT1 likely acts in the
RTK/MAPK pathway to promote tumorigenesis. In agreement with
this notion is the recent identiﬁcation of germline RIT1 mutations
in Noonan syndrome, a developmental disorder caused by
mutations in RAS-pathway genes.
36 In cancer, targeted inhibition
of PI3K and MEK should be explored as a possible therapeutic
strategy for patients with RIT1 mutations.
MATERIALS AND METHODS
Identiﬁcation of mutations
Somatic RIT1 mutations were identiﬁed in two independent cohorts of
lung adenocarcinoma sequence data from Imielinski et al.
1 or The Cancer
Genome Atlas (http://cancergenome.nih.gov, manuscript submitted).
Construct generation and virus production
pDONR223-RIT1 was obtained from the Broad Institute’s ORF collection
37
and conﬁrmed to be wild-type by Sanger sequencing. Mutations were
introduced into pDONR223-RIT1 by site-directed mutagenesis using the
Quikchange II kit (Agilent Technologies, Santa Clara, CA, USA) according to
the manufacturer’s protocol. Primer sequences are available upon request.
Figure 3. Endogenous mutated RIT1 regulates MEK and PI3K in NCI-H2110 cells. (a) Sanger sequencing of RIT1 RT–PCR products generated from
NCI-H1993 or NCI-H2110 cell line cDNA. Numbering in black bold refers to amino-acid positions and colored letters refer to nucleotide sequence.
An arrow indicates the position of a heterozygous p.M90I mutation. (b) Western blot of lysates from NCI-H1299 and NCI-H2110 following
expression of shRNA hairpins targeting RIT1 (shRIT1-1, -2 and -3) or non-targeting hairpin control (shlacZ). (c) Tumor volume of NCI-H2110
xenografts in nude mice. 2 10
6 cells were injected subcutaneously into the ﬂanks of nude mice. When tumors reached B100mm
3,d r u g
treatment was initiated (day 0). Mice were treated daily with 150mg/kg GDC-0941 or vehicle control by oral gavage. *Po0.05. n¼9t u m o r sp e r
condition. (d) Weight of tumors from NCI-H2110 xenografts shown in b. At day 18, animals were euthanized and tumors excised and weighed.
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generation of retrovirus or p3xFlag-CMV10 (Sigma-Aldrich, St Louis, MO,
USA) for transient transfection experiments. Retrovirus was generated by co-
transfection of pBabe-puro and a pCL-Eco packaging vector into 293T cells
using Fugene6 (Promega, Madison, WI, USA). Forty-eight hours post-
transfection, virus was harvested and ﬁltered through a 0.45mm syringe ﬁlter
before addition to exponentially growing NIH3T3 cells. Forty-eight hours
post-infection, cells were selected with 2mg/ml puromycin for 2–3 days
before proceeding with downstream soft agar assays or other experiments.
Cell line sequencing
We considered ‘known’ adenocarcinoma oncogenes as previously
deﬁned,
2 with the addition of the recently identiﬁed MET exon 14
skipping variant.
16,38 We curated the genotypes of these genes in 64 non-
squamous cell lines (Supplementary Table 5) from previously generated
Oncomap data.
39,40 Nineteen cell lines lacking known lung adeno-
carcinoma oncogenes and three control cell lines were selected for RIT1
cDNA sequencing. Cell line culturing and cDNA preparation was as
previously described.
41 The switch II domain region of RIT1 was PCR
ampliﬁed using the following primers: RIT1-c-ex3-F, TCATCAGCCACCG
ATTCC; RIT1-c-ex5-R, CGTCGGACTCGATAAATAAGC. PCR was performed
using the HotStarTaq mastermix (Qiagen, Valencia, CA, USA) with the
following thermocycling conditions: 5min at 951C, 38 cycles of 15s at
941C, 1min at 501C, 1min at 721C and an additional extension time of
10min at 721C. PCR products were puriﬁed using the Qiaquick PCR
puriﬁcation kit (Qiagen) and sequenced by Sanger sequencing (Genewiz,
Cambridge, MA, USA) using the same primers as above. Seqman (DNAStar,
Madison, WI, USA) was used to align sequencing traces and identify single
nucleotide polymorphisms. The p.M90I mutation identiﬁed in NCI-H2110
cells was validated in an independent cDNA sample from an independent
aliquot of cells obtained directly from ATCC.
Soft agar assay
NIH3T3 cells were transduced with retrovirus generated with pBabe-puro-
RIT1 plasmids or pBabe-puro empty vector. Forty-eight hours post-
infection, cells were selected with 2ug/ml puromycin. After 48h of
selection, cells were split for seeding in a soft agar assay or lysis for
veriﬁcation of protein expression by western blotting. For the soft agar
assay, 5 10
3–5 10
4 cells were suspended in 1ml of 0.33% select agar in
DMEM/FBS and plated on a bottom layer of 0.5% select agar in DMEM/FBS
in six-well dishes. Each cell line/mutation was analyzed in triplicate.
Colonies were photographed after 14–21 days and quantiﬁed using
CellProﬁler.
42 An anti-RIT1 antibody (#ab13322, Abcam, Cambridge, UK)
and an anti-vinculin (loading control) antibody (Sigma-Aldrich) were used
to conﬁrm RIT1 expression. For soft agar inhibitor experiments, AZD6244,
erlotinib or GDC-0941 were purchased from Selleckchem, Houston, TX, USA
and suspended in the top agar solution at a ﬁnal concentration of 1mM.
Agar wells were hydrated weekly with media containing 1mM drug.
Xenograft assays
Xenografts were performed as previously described.
43 For transformation
assays, RIT1- or empty vector-transduced NIH3T3 cells, generated as above,
were harvested by trypsinization, washed in PBS and resuspended at
10
6cells/ml in PBS. Two hundred microliters (2 10
5 cells) were injected
into each injection site, n¼9 sites per cell line, in 4–6-week-old female nu/
nu mice (Jackson Laboratory, Bar Harbor, ME, USA). Cells were allowed to
engraft for 1 week, then tumors were measured every 3 days using a
digital caliper (VWR, Radnor, PA, USA). Tumor volume was calculated with
the formula 0.5 L W
2 where L is the longest diameter and W is the
diameter perpendicular to L. NCI-H2110 studies, cells were prepared as
above and then resuspended at 10
7cells/ml. Two hundred microliters
(2 10
6 cells) were injected per site into ﬂanks of nu/nu mice. Tumors
were monitored until B100mm
3, at which time inhibitor dosing was
initiated. GDC-0941 (Selleckchem) was resuspended at 20mg/ml in 0.5%
methylcellulose/0.2% Tween-80 and 150mg/kg administered daily by oral
gavage. All animal experiments were carried out in accordance with the
DFCI Institutional Animal Care and Use Committee guidelines.
Antibodies and cell culture
Monolayers of PC6 cells were transfected with 2mg of plasmid DNA per
well of a six-well plate as described previously.
31 After a 60h incubation,
whole cell lysates were prepared in kinase lysis buffer, an equal amount of
protein from each lysate was resolved by 10% SDS–PAGE and subjected to
immunoblot analysis with the indicated antibody as described pre-
viously.
31 For inhibitor experiments, cells were pre-treated with 10mM
PD98059 or LY294002 or dimethylsulfoxide for 30min prior to transfection.
60h post-transfection, cells were serum-starved for 5h in the presence of
the inhibitor or dimethylsulfoxide before lysis in kinase buffer. Commercial
antibodies were used to total- and phospho-speciﬁc MEK, ERK, AKT (Cell
Signaling, Danvers, MA, USA), Flag (Sigma-Aldrich) and RIT1 (Abcam).
Knockdown experiments
Hairpins targeting RIT1 (shRIT1-1, -2 and -3) and a non-targeting hairpin
(shLacZ) were obtained from The RNAi Consortium (TRC) in the pLKO
lentiviral backbone. Virus was generated by co-transfection of pLKO, VSV-G
and D8.9 packaging vectors in 293T cells. Lentivirus was harvested in
DMEMþ30% FBS and ﬁltered or frozen before application to exponentially
growing NCI-H1299 or NCI-H2110 cells. Cells were selected in 2mg/ml
puromycin for 3 days and then expanded for 1–2 weeks before analysis.
Hairpin TRC clone IDs and target sequences were as follows:
shLacZ,/TRCN0000072223, TGTTCGCATTATCCGAACCAT
shRIT1-1/TRCN0000047888, CGCTACTATATTGATGATGTT
shRIT1-2/CGTCGAAGTTTCCATGAAGTT, CGTCGAAGTTTCCATGAAGTT
shRIT1-3/TRCN0000047890, CGAGAATTCAGCTGTCCCTTT.
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